AbaloparatideGH BoosterSafety Rating 8/10
Primary research areaPostmenopausal osteoporosis at high fracture risk
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range80 mcg once daily SC
AdministrationSubcutaneous injection
Safety8/10 · FDA-approved (Tymlos)
NCAA D1Not listed
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Abaloparatide
Mechanism of action
PTH-related protein analog; selective PTH1R agonist with preferential anabolic bone effects
Safety profile
Dizziness, nausea, palpitations, osteosarcoma risk (boxed warning) · Approved for osteoporosis; dizziness, nausea, injection site reactions; 2-year limit due to animal osteosarcoma data
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Abaloparatide below your target.
Related pages